S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
What to Expect from the Markets in a Recession
pixel
China July exports rise, with trade surplus at record-high
What's in Democrats' big bill? Climate, health care, savings
Shift in war's front seen as ships cleared to leave Ukraine
pixel
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
What to Expect from the Markets in a Recession
pixel
China July exports rise, with trade surplus at record-high
What's in Democrats' big bill? Climate, health care, savings
Shift in war's front seen as ships cleared to leave Ukraine
pixel
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
What to Expect from the Markets in a Recession
pixel
China July exports rise, with trade surplus at record-high
What's in Democrats' big bill? Climate, health care, savings
Shift in war's front seen as ships cleared to leave Ukraine
pixel
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
What to Expect from the Markets in a Recession
pixel
China July exports rise, with trade surplus at record-high
What's in Democrats' big bill? Climate, health care, savings
Shift in war's front seen as ships cleared to leave Ukraine
pixel
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
pixel
NASDAQ:VBLT

Vascular Biogenics - VBLT Stock Forecast, Price & News

$0.24
-0.01 (-2.67%)
(As of 08/5/2022 08:49 PM ET)
Add
Compare
Today's Range
$0.23
$0.24
50-Day Range
$0.22
$2.10
52-Week Range
$0.21
$2.54
Volume
3.74 million shs
Average Volume
1.14 million shs
Market Capitalization
$16.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.88

Vascular Biogenics MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
1,961.3% Upside
$4.88 Price Target
Short Interest
Healthy
0.61% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.62mentions of Vascular Biogenics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.51) to ($0.54) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.95 out of 5 stars

Medical Sector

761st out of 1,283 stocks

Pharmaceutical Preparations Industry

368th out of 615 stocks

VBLT stock logo

About Vascular Biogenics (NASDAQ:VBLT) Stock

Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables specifically inhibit monocyte migration for immune-inflammatory applications. The company's lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.

Receive VBLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vascular Biogenics and its competitors with MarketBeat's FREE daily newsletter.

VBLT Stock News Headlines

Vascular Biogenics (NASDAQ:VBLT) Now Covered by StockNews.com
Vascular Biogenics Cutting About 35% of Staff >VBLT
VBL Therapeutics Announces Workforce Reduction
Vascular Biogenics (NASDAQ:VBLT) Downgraded by HC Wainwright
Vascular Biogenics Earnings Preview
Vascular Biogenics earnings: here's what Wall Street expects
See More Headlines
Receive VBLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vascular Biogenics and its competitors with MarketBeat's FREE daily newsletter.

VBLT Company Calendar

Last Earnings
5/17/2022
Today
8/07/2022
Next Earnings (Estimated)
8/15/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VBLT
Previous Symbol
NASDAQ:VBLX
Employees
41
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.88
High Stock Price Forecast
$5.50
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+1,961.3%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Net Income
$-29,920,000.00
Net Margins
-4,894.40%
Pretax Margin
-3,703.30%

Debt

Sales & Book Value

Annual Sales
$770,000.00
Book Value
$0.73 per share

Miscellaneous

Free Float
N/A
Market Cap
$16.40 million
Optionable
Optionable
Beta
0.57

Key Executives

  • Prof. Dror Harats M.D. (Age 65)
    CEO & Director
  • Dr. Eyal Breitbart Ph.D. (Age 55)
    Sr. VP of Research & Operations
  • Dr. Naamit Sher Ph.D. (Age 68)
    Sr. VP of Drug Devel. & Regulatory Affairs
  • Dr. Erez Feige M.B.A. (Age 48)
    Ph.D., Sr. VP of Bus. Operations
  • Mr. Amos Ron (Age 67)
    Company Sec.
  • Mr. Samuel Backenroth (Age 38)
    Chief Financial Officer
  • Advocate Ayelet Horn (Age 51)
    Gen. Counsel
  • Deborah Scott
    Managing Director of Financial Communications
  • Dr. Tami Rachmilewitz M.D. (Age 52)
    Sr. VP of Clinical Devel.
  • Mr. Matthew Trudeau M.Sc.
    Chief Commercial Officer













VBLT Stock - Frequently Asked Questions

Should I buy or sell Vascular Biogenics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vascular Biogenics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Vascular Biogenics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VBLT, but not buy additional shares or sell existing shares.
View analyst ratings for Vascular Biogenics
or view top-rated stocks.

What is Vascular Biogenics' stock price forecast for 2022?

4 equities research analysts have issued twelve-month target prices for Vascular Biogenics' stock. Their VBLT stock forecasts range from $4.00 to $5.50. On average, they predict Vascular Biogenics' stock price to reach $4.88 in the next twelve months. This suggests a possible upside of 1,961.3% from the stock's current price.
View analysts' price targets for Vascular Biogenics
or view top-rated stocks among Wall Street analysts.

How has Vascular Biogenics' stock performed in 2022?

Vascular Biogenics' stock was trading at $1.97 at the beginning of 2022. Since then, VBLT stock has decreased by 88.0% and is now trading at $0.2365.
View the best growth stocks for 2022 here
.

When is Vascular Biogenics' next earnings date?

Vascular Biogenics is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our earnings forecast for Vascular Biogenics
.

How were Vascular Biogenics' earnings last quarter?

Vascular Biogenics Ltd. (NASDAQ:VBLT) issued its quarterly earnings results on Tuesday, May, 17th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by $0.01. The biopharmaceutical company earned $0.11 million during the quarter, compared to analyst estimates of $0.20 million. Vascular Biogenics had a negative trailing twelve-month return on equity of 69.21% and a negative net margin of 4,894.40%. During the same period in the prior year, the business posted ($0.12) EPS.

What other stocks do shareholders of Vascular Biogenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vascular Biogenics investors own include SCYNEXIS (SCYX), Matinas BioPharma (MTNB), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Aeterna Zentaris (AEZS), Dynavax Technologies (DVAX), Vaxart (VXRT) and Geron (GERN).

What is Vascular Biogenics' stock symbol?

Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT."

How do I buy shares of Vascular Biogenics?

Shares of VBLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vascular Biogenics' stock price today?

One share of VBLT stock can currently be purchased for approximately $0.24.

How much money does Vascular Biogenics make?

Vascular Biogenics (NASDAQ:VBLT) has a market capitalization of $16.40 million and generates $770,000.00 in revenue each year. The biopharmaceutical company earns $-29,920,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis.

How many employees does Vascular Biogenics have?

Vascular Biogenics employs 41 workers across the globe.

How can I contact Vascular Biogenics?

Vascular Biogenics' mailing address is 8 HASATAT STREET, MODI IN L3, 7178106. The official website for Vascular Biogenics is www.vblrx.com. The biopharmaceutical company can be reached via phone at (728) 993-5000, via email at ir@vblrx.com, or via fax at 972-8993-5001.

This page (NASDAQ:VBLT) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.